Alzheimer's disease (AD), Dementia with Lewy bodies (DLB), and Parkinson's disease with dementia (PDD) are neurodegenerative disorders that lead to a global dementia syndrome. Despite differences in the prominence and order of appearance of various clinical characteristics (e.g., dementia, movement disorder, visual hallucinations), the disorders can be quite similar in clinical presentation once dementia is present, making them difficult to clinically differentiate (particularly AD vs. DLB and DLB vs. PDD). Recent evidence suggests that differences in the patterns of cognitive deficits associated with the disorders might aid in distinguishing between them and have some utility in predicting rate of global cognitive decline. Thus, the goal of the proposed project is to determine whether mildly demented DLB, PDD, and AD patients differ in the relative severity of deficits they exhibit on experimental and clinical neuropsychological tests (Study I). Based upon the different distributions of pathological changes associated with the three disorders it is anticipated that semantic knowledge and episodic memory deficits will be most salient in AD, visuospatial processing deficits will be most salient in DLB, and implicit category learning deficits will be most salient in PDD. Furthermore, we will determine whether or not unique patterns of deficits on these tests are maintained over a one-year period (Study II). Previous evidence suggests that the degree of impairment in the most salient cognitive deficit in each disorder predicts the rate of subsequent global cognitive decline. We will address this question by directly comparing the cognitive predictors of decline in three disorders (Studies Illa-c). We anticipate that degree of semantic memory loss (and not the lack of integrity in other cognitive functions) will uniquely predict decline in AD, severity of visuospatial processing deficits will uniquely predict decline in DLB, and degree of category learning impairment will uniquely predict decline in PDD. In exploratory studies (Studies IV-VI), we will examine the relationship between the degree of impairment on the cognitive tests from each domain and the severity of neuropathologic changes in the presumed underlying brain substrate. We anticipate that posterior cortical pathology (e.g., a-synuclein pathology, (3-amyloid and tau pathology, synapse loss) will be associatedwith visuospatial dysfunction and decline (DLB

Public Health Relevance

(Seeinstructions): Identification of differences in the neuropsychological deficits in AD, DLB, and PDD will allow us to better differentiate among the three disorders and facilitate early diagnosis. Validation of cognitive markers that predict subsequent rate of global cognitive decline will improve the accuracy of prognosis and may provide a method to enhance cohorts with rapid decliners for clinical trials of potential disease modifying therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-29
Application #
8375271
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
29
Fiscal Year
2012
Total Cost
$176,682
Indirect Cost
$39,190
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Blue, Elizabeth E; Bis, Joshua C; Dorschner, Michael O et al. (2018) Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. Dement Geriatr Cogn Disord 45:1-17
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Golde, Todd E; DeKosky, Steven T; Galasko, Douglas (2018) Alzheimer's disease: The right drug, the right time. Science 362:1250-1251
Young, Jessica E; Fong, Lauren K; Frankowski, Harald et al. (2018) Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem Cell Reports 10:1046-1058
Reas, Emilie T; Hagler Jr, Donald J; White, Nathan S et al. (2018) Microstructural brain changes track cognitive decline in mild cognitive impairment. Neuroimage Clin 20:883-891
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307

Showing the most recent 10 out of 914 publications